Verona Pharma PLC American Depositary Share (VRNA) to Release Quarterly Earnings on Thursday

Key Points

• Verona Pharma PLC is set to release its Q2 2025 earnings on Thursday, August 14th, with analysts expecting earnings of $0.39 per share and revenue of $68.24 million.
• The company's shares have recently experienced changes in analyst ratings, with several firms downgrading them from a "strong-buy" to a "hold" rating, and an average target price of $109.00.
• Insiders have sold significant amounts of stock recently, with CFO Mark W. Hahn selling 400,000 shares valued at approximately $4.56 million, representing a decrease in their ownership position by 3.15%.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of $0.39 per share and revenue of $68.24 million for the quarter.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.14. The business had revenue of $103.14 million during the quarter, compared to the consensus estimate of $90.41 million. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. On average, analysts expect Verona Pharma PLC American Depositary Share to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Verona Pharma PLC American Depositary Share Price Performance

Shares of Verona Pharma PLC American Depositary Share stock traded down $0.12 during trading hours on Friday, reaching $105.28. The stock had a trading volume of 610,545 shares, compared to its average volume of 4,298,595. The stock's 50 day moving average is $97.20 and its 200 day moving average is $75.68. The firm has a market capitalization of $8.96 billion, a PE ratio of -106.34 and a beta of 0.12. Verona Pharma PLC American Depositary Share has a twelve month low of $21.56 and a twelve month high of $105.50. The company has a current ratio of 10.71, a quick ratio of 8.73 and a debt-to-equity ratio of 0.87.

Insider Activity at Verona Pharma PLC American Depositary Share

In related news, CFO Mark W. Hahn sold 400,000 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the completion of the transaction, the chief financial officer owned 12,278,992 shares of the company's stock, valued at approximately $139,980,508.80. This trade represents a 3.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kathleen A. Rickard sold 58,336 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $766,535.04. Following the transaction, the insider directly owned 2,607,472 shares of the company's stock, valued at $34,262,182.08. The trade was a 2.19% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,220,584 shares of company stock worth $24,613,268. Company insiders own 4.80% of the company's stock.

Hedge Funds Weigh In On Verona Pharma PLC American Depositary Share

Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada boosted its position in Verona Pharma PLC American Depositary Share by 43.3% in the 1st quarter. Royal Bank of Canada now owns 9,719 shares of the company's stock valued at $617,000 after buying an additional 2,938 shares during the period. NewEdge Advisors LLC purchased a new position in Verona Pharma PLC American Depositary Share in the 1st quarter valued at approximately $58,000. Goldman Sachs Group Inc. boosted its position in Verona Pharma PLC American Depositary Share by 274.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company's stock valued at $66,119,000 after buying an additional 763,353 shares during the period. Geneos Wealth Management Inc. boosted its position in Verona Pharma PLC American Depositary Share by 44.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after buying an additional 193 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in Verona Pharma PLC American Depositary Share in the 1st quarter valued at approximately $48,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Analyst Upgrades and Downgrades

VRNA has been the subject of several research analyst reports. Wells Fargo & Company downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and reduced their price target for the stock from $138.00 to $107.00 in a research report on Thursday, July 10th. BTIG Research downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Jefferies Financial Group reiterated a "hold" rating and issued a $107.00 price objective (down previously from $140.00) on shares of Verona Pharma PLC American Depositary Share in a report on Wednesday, July 9th. TD Cowen downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Wednesday, July 9th. Finally, Piper Sandler downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Eleven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $109.00.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.